Delcath Systems, Inc. (NASDAQ:DCTH) Receives Consensus Rating of “Moderate Buy” from Analysts

Delcath Systems, Inc. (NASDAQ:DCTH) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $22.50.

DCTH has been the subject of several analyst reports. Stephens dropped their price objective on Delcath Systems from $25.00 to $18.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Delcath Systems in a research report on Friday, January 9th. Evercore set a $27.00 price objective on shares of Delcath Systems in a research note on Thursday. Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a research report on Monday, December 29th. Finally, BTIG Research cut their price target on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a report on Thursday.

Delcath Systems Stock Down 1.1%

NASDAQ DCTH opened at $8.90 on Monday. The firm has a 50-day moving average price of $9.98 and a two-hundred day moving average price of $10.19. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $18.23. The company has a market capitalization of $309.28 million, a P/E ratio of 127.14 and a beta of 0.38.

Delcath Systems (NASDAQ:DCTH) last announced its earnings results on Thursday, March 5th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. Delcath Systems had a net margin of 3.17% and a return on equity of 2.70%. The company had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $20.35 million. Equities analysts expect that Delcath Systems will post -0.79 EPS for the current year.

Delcath Systems announced that its board has authorized a stock repurchase program on Thursday, November 20th that allows the company to buyback $25.00 million in shares. This buyback authorization allows the company to repurchase up to 8.6% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC lifted its position in shares of Delcath Systems by 34.1% during the 1st quarter. Millennium Management LLC now owns 422,066 shares of the company’s stock worth $5,373,000 after buying an additional 107,391 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Delcath Systems by 58.7% during the first quarter. Goldman Sachs Group Inc. now owns 123,487 shares of the company’s stock worth $1,572,000 after acquiring an additional 45,695 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Delcath Systems in the second quarter worth about $1,338,000. Campbell & CO Investment Adviser LLC bought a new position in shares of Delcath Systems in the second quarter worth about $162,000. Finally, Geode Capital Management LLC boosted its stake in shares of Delcath Systems by 128.1% in the 2nd quarter. Geode Capital Management LLC now owns 703,171 shares of the company’s stock valued at $9,565,000 after purchasing an additional 394,902 shares in the last quarter. Institutional investors own 61.12% of the company’s stock.

Trending Headlines about Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Company reported Q4 and full‑year 2025 results with Q4 revenue of $20.7M and full‑year revenue of $85.2M; EPS of ($0.05) beat consensus by $0.01 — evidence of improving commercial execution. BusinessWire Release
• Positive Sentiment: Management is targeting at least $100M in revenue for 2026 and plans to expand to ~40 treatment centers, signaling a clear growth roadmap and potential material revenue upside if execution continues. Seeking Alpha
• Neutral Sentiment: Company updated FY‑2026 revenue guidance to ~$100.0M (effectively in line with consensus ~100.1M); guidance confirms the growth target but leaves little upside vs. street estimates absent faster center rollout or higher per‑center revenue. MarketBeat Earnings
• Neutral Sentiment: BTIG cut its price target from $23 to $19 but kept a “buy” rating—still implying substantial upside from current levels, though the downgrade signals more conservative near‑term expectations from at least one sell‑side shop. Street Insider

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.